Data on Oncotype DX breast cancer diagnostic demonstrates benefits for surgery assessments- Genomic Health

Genomic Health announced results from 15 Oncotype DX studies across 12 countries, providing real-world evidence of the test's ability to change treatment decisions in breast cancer patients. New findings included a summary of outcomes from nine studies involving more than 600 early-stage breast cancer patients who underwent neoadjuvant therapy. Results included from the findings from a key prospective multi-centre study involved the Breast Cancer Centre, Centre Hospitalier de l'Universit� de Montr�al, Quebec, Canada.

The Oncotype DX Breast Recurrence Score test was performed on core biopsies in these patients prior to receiving either neoadjuvant chemotherapy or neoadjuvant hormone therapy. The analysis showed that for patients with a Recurrence Score result below 25, treatment with neoadjuvant hormonal therapy alone could be an effective treatment strategy to achieve BCS. Such patients could thus potentially avoid chemotherapy without reducing their chances of successful BCS. It demonstrated that analyzing tumour biology with the Oncotype DX test could identify patients unlikely to benefit from chemotherapy prior to breast cancer surgery (neoadjuvant setting) and more likely to achieve successful clinical response and breast-conserving surgery with neoadjuvant hormone therapy and highlight the test's utility in guiding treatment decisions without compromising outcomes. Data was presented at the 15th St. Gallen International Breast Cancer Conference in Vienna.